Q3 2025 BioMarin Pharmaceutical Inc Earnings Call Transcript
Key Points
- BioMarin Pharmaceutical Inc (BMRN) reported an 11% increase in top-line growth year-over-year, driven by strong performance in global Enzyme Therapies and skeletal conditions business units.
- The company raised its full-year total revenue guidance at the midpoint and reaffirmed its VOXZOGO revenue outlook for 2025.
- BioMarin's Enzyme Therapies business unit has grown into a $2 billion-plus franchise over the last 12 months, with continued growth anticipated.
- VOXZOGO, the treatment for achondroplasia, is expected to generate more than $900 million in revenues this year, representing 25% growth at the midpoint of guidance.
- The company has a strong cash and investments balance of approximately $2 billion, supporting future growth and business development opportunities.
- BioMarin is facing potential competition for VOXZOGO, which could impact future revenue growth.
- The company announced a $221 million charge for acquired in-process research and development related to the Enzyme's Pharma acquisition, impacting GAAP and non-GAAP R&D expenses.
- Operating margin and diluted earnings per share were lower year-over-year due to higher SG&A investments and the IPR&D charge.
- BioMarin is pursuing options to divest Roctavian, indicating a strategic shift and potential loss of revenue from this gene therapy.
- The company has not provided a specific estimate or narrow range for 2027 revenues due to many unknowns and variables impacting future revenue.
Hello, and welcome to the BioMarin Pharmaceutical third-quarter 2025 conference call. (Operator Instructions)
I would now like to turn the conference over to Traci McCarty. Please go ahead.
Thank you, operator. To remind you, this nonconfidential presentation contains forward-looking statements about the business prospects of BioMarin Pharmaceutical Inc., including expectations regarding BioMarin's financial performance, commercial products and potential future products in different areas of therapeutic research and development.
Results may differ materially depending on the progress of BioMarin's product programs, actions of regulatory authorities, availability of capital, future actions in the pharmaceutical market and developments by competitors and those factors detailed in BioMarin's filings with the Securities and Exchange Commission, such as 10-Q, 10-K and 8-K reports.
In addition, we will use non-GAAP financial metrics as defined in
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
